HEPZATO (Melphalan Hydrochloride) Patent Expiration, LOE Window & CMS Spending

HEPZATO (Melphalan Hydrochloride) by Delcath Systems: FDA Orange Book core substance LOE 2034-09-17, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $182,500 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorDelcath Systems
FDA Application & PathwayN201848 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2034-09-17
Last Listed Patent or Exclusivity Date2034-09-17
Orange Book Patents (*PED Extensions)11 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($182,500 intro WAC)